We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
Read MoreHide Full Article
Key Takeaways
Moderna raises its 2026 revenue growth outlook to 15-25% after Q3 sales jumped 29% to $1.31 billion.
MRNA posts Q3 earnings of 38 cents per share as R&D expenses decline 27% to $583 million.
Moderna's melanoma therapy cuts recurrence or death risk by 42%, with a regulatory filing targeted for 2026.
Moderna, Inc. (MRNA - Free Report) raised its 2026 revenue outlook following stronger-than-expected third-quarter sales, supported by increased COVID vaccine demand, international partnerships and improved commercial execution.
During the earnings call, management emphasized cost discipline, respiratory vaccine expansion and progress in oncology, particularly positive late-stage melanoma data for its individualized cancer therapy, intismeran autogene.
MRNA Raises Revenue Outlook After Strong Q3
Chief financial officer Jamey Mock raised the company's 2026 revenue growth guidance to 15-25% compared with its previous expectation of up to 10% growth. Management expects approximately equal contributions from U.S. and international markets.
Third-quarter revenues increased 29% year over year to $1.31 billion, exceeding the Zacks Consensus Estimate of $0.89 billion by 47.70%. Revenues totaled $1.8 billion for the first nine months of 2026.
Mock attributed the improvement to stronger demand, increased mNEXSPIKE adoption, international execution and shipment timing between the third and fourth quarters. U.S. sales accounted for approximately 60% of quarterly revenues.
Moderna Reports Earnings Beat and Lower Costs
Moderna reported earnings of 38 cents per share against a loss of 51 cents a year earlier. The result surpassed the Zacks Consensus Estimate of a loss of $1.10 per share, representing a 134.60% earnings surprise.
Net income reached $162 million, reversing the prior-year loss of $200 million. Research and development expenses declined 27% to $583 million, reflecting study wind-downs and operating efficiencies.
Mock reduced the 2026 R&D expense forecast to approximately $2.7 billion from $2.9 billion. The company now expects adjusted cash costs of $3.8 billion and year-end cash and investments of $8.1-$8.3 billion.
MRNA Expands Its Respiratory Vaccine Portfolio
President Stephen Hoge highlighted FDA approval of mFLUSIVA, Moderna's influenza vaccine, alongside Canadian approvals for mFLUSIVA and the flu-COVID combination vaccine mCOFLU.
Hoge reported increased mNEXSPIKE uptake in the United States and progress across strategic international partnerships. Moderna also signed a five-year agreement supporting COVID vaccine supply in Mexico.
The company cited stable U.S. respiratory vaccination demand, with approximately 44.1 million vaccinations administered through retail and long-term care channels by late October, representing 3% growth over the comparable prior-year period.
Moderna Advances Intismeran Toward Regulatory Filing
Chief development officer David Berman highlighted Phase III melanoma data showing a 42% reduction in recurrence or death risk with intismeran plus KEYTRUDA compared with KEYTRUDA alone.
A prespecified modified intent-to-treat analysis demonstrated a 49% risk reduction. Management emphasized the consistency between these findings and earlier Phase II results.
During Q&A, a Morgan Stanley analyst questioned potential pricing, while a Piper Sandler analyst sought clarity on regulatory preparations. Hoge said Moderna and Merck were working toward a biologics license application submission in 2026, with potential approval in 2027.
MRNA Faces Questions on Pipeline Execution
A Goldman Sachs analyst questioned confidence in the upcoming renal cell carcinoma readout. Berman cited intismeran's melanoma efficacy and the biological characteristics of renal cancer while emphasizing that the study's timing remains event-driven.
Management also addressed its norovirus vaccine program, mRNA-1403, after its Phase III interim analysis failed to meet statistical criteria for early success.
Hoge confirmed that Moderna would not enroll another cohort this season and would instead consult regulators before determining the program's next steps.
Moderna Maintains Focus on Growth and Financial Discipline
CEO Stéphane Bancel emphasized commercial expansion, operating efficiency and oncology development as Moderna's principal priorities.
The company also strengthened its financing position through $3 billion of zero-coupon convertible notes, generating approximately $2.6 billion in net proceeds after capped-call purchases and fees.
Zacks Rank and Style Scores Signal Caution
Moderna currently carries a Zacks Rank #3 (Hold), indicating a neutral near-term earnings-revision outlook.
Its Value Score of F, Growth Score of C and Momentum Score of F indicate relatively unfavorable characteristics across several investment styles.
The company's VGM Score of F also points to weak combined value, growth and momentum attributes. Although the Zacks Rank #3 supports a neutral stance, the unfavorable Style Scores limit its attractiveness under the Zacks screening framework. The Zacks Rank may change as analysts revise their earnings estimates following the reported results.
View the Zacks #1 Rank List
Image: Bigstock
Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology
Key Takeaways
Moderna, Inc. (MRNA - Free Report) raised its 2026 revenue outlook following stronger-than-expected third-quarter sales, supported by increased COVID vaccine demand, international partnerships and improved commercial execution.
During the earnings call, management emphasized cost discipline, respiratory vaccine expansion and progress in oncology, particularly positive late-stage melanoma data for its individualized cancer therapy, intismeran autogene.
MRNA Raises Revenue Outlook After Strong Q3
Chief financial officer Jamey Mock raised the company's 2026 revenue growth guidance to 15-25% compared with its previous expectation of up to 10% growth. Management expects approximately equal contributions from U.S. and international markets.
Third-quarter revenues increased 29% year over year to $1.31 billion, exceeding the Zacks Consensus Estimate of $0.89 billion by 47.70%. Revenues totaled $1.8 billion for the first nine months of 2026.
Mock attributed the improvement to stronger demand, increased mNEXSPIKE adoption, international execution and shipment timing between the third and fourth quarters. U.S. sales accounted for approximately 60% of quarterly revenues.
Moderna Reports Earnings Beat and Lower Costs
Moderna reported earnings of 38 cents per share against a loss of 51 cents a year earlier. The result surpassed the Zacks Consensus Estimate of a loss of $1.10 per share, representing a 134.60% earnings surprise.
Moderna, Inc. Price, Consensus and EPS Surprise
Moderna, Inc. price-consensus-eps-surprise-chart | Moderna, Inc. Quote
Net income reached $162 million, reversing the prior-year loss of $200 million. Research and development expenses declined 27% to $583 million, reflecting study wind-downs and operating efficiencies.
Mock reduced the 2026 R&D expense forecast to approximately $2.7 billion from $2.9 billion. The company now expects adjusted cash costs of $3.8 billion and year-end cash and investments of $8.1-$8.3 billion.
MRNA Expands Its Respiratory Vaccine Portfolio
President Stephen Hoge highlighted FDA approval of mFLUSIVA, Moderna's influenza vaccine, alongside Canadian approvals for mFLUSIVA and the flu-COVID combination vaccine mCOFLU.
Hoge reported increased mNEXSPIKE uptake in the United States and progress across strategic international partnerships. Moderna also signed a five-year agreement supporting COVID vaccine supply in Mexico.
The company cited stable U.S. respiratory vaccination demand, with approximately 44.1 million vaccinations administered through retail and long-term care channels by late October, representing 3% growth over the comparable prior-year period.
Moderna Advances Intismeran Toward Regulatory Filing
Chief development officer David Berman highlighted Phase III melanoma data showing a 42% reduction in recurrence or death risk with intismeran plus KEYTRUDA compared with KEYTRUDA alone.
A prespecified modified intent-to-treat analysis demonstrated a 49% risk reduction. Management emphasized the consistency between these findings and earlier Phase II results.
During Q&A, a Morgan Stanley analyst questioned potential pricing, while a Piper Sandler analyst sought clarity on regulatory preparations. Hoge said Moderna and Merck were working toward a biologics license application submission in 2026, with potential approval in 2027.
MRNA Faces Questions on Pipeline Execution
A Goldman Sachs analyst questioned confidence in the upcoming renal cell carcinoma readout. Berman cited intismeran's melanoma efficacy and the biological characteristics of renal cancer while emphasizing that the study's timing remains event-driven.
Management also addressed its norovirus vaccine program, mRNA-1403, after its Phase III interim analysis failed to meet statistical criteria for early success.
Hoge confirmed that Moderna would not enroll another cohort this season and would instead consult regulators before determining the program's next steps.
Moderna Maintains Focus on Growth and Financial Discipline
CEO Stéphane Bancel emphasized commercial expansion, operating efficiency and oncology development as Moderna's principal priorities.
The company also strengthened its financing position through $3 billion of zero-coupon convertible notes, generating approximately $2.6 billion in net proceeds after capped-call purchases and fees.
Zacks Rank and Style Scores Signal Caution
Moderna currently carries a Zacks Rank #3 (Hold), indicating a neutral near-term earnings-revision outlook.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Its Value Score of F, Growth Score of C and Momentum Score of F indicate relatively unfavorable characteristics across several investment styles.
The company's VGM Score of F also points to weak combined value, growth and momentum attributes. Although the Zacks Rank #3 supports a neutral stance, the unfavorable Style Scores limit its attractiveness under the Zacks screening framework. The Zacks Rank may change as analysts revise their earnings estimates following the reported results.